Peptides DB
Research-centric peptide and protocol reference hub

KLOW Protocol record · updated 18h ago

Healing & recoveryMetabolic & appetiteGrade D · emergingResearch use only
Evidence for its componentsCompare
What is KLOW Protocol used for?

KLOW is a four-peptide compounded blend (typically KPV, LL-37, GHK, and Wolverine-style healing peptides) studied informally for combined regenerative and metabolic effects.

Primarily researched for · Healing & recovery

Development stage

where KLOW Protocol sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity
NameKLOW Protocol
Chain length—
Molecular weight—
Formula—
Structure type—
ClassWeight Loss
Research levelLimited Research
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies0
Human / animal / cellular0 / 0 / 0
Highest trial phase—
Years covered—
Latest study—
Publication history
No publication years on file
——
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

no studies of its own · newest 12 of 74 from its componentsOpen in the library →
No direct evidence

No study in this library has tested this combination directly. The papers below examined its components individually — each row is labelled with the single compound that study looked at.

Evidence for one component is not evidence for the combination. Nothing below measured what happens when these compounds are used together.

StudyTypeYearSummary depth
GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.
FindingNot reported in abstract.
review2026Full text read0.80
BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.
FindingNot reported in abstract.
review2020Full text read0.70
A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials.
FindingNot reported in abstract.
review2026Full text read0.80
Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells.
TakeawayNot reported in abstract.
—1980Title only0.10
The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I).
TakeawayNot reported in abstract.
—1996Title only0.10
The Regenerative Potential of GHK-Cu in Aesthetic Medicine.
FindingNot reported in abstract.
review2026Full text read0.70
De novo cardiomyocytes from within the activated adult heart after injury.
TakeawayNot reported in abstract.
—2011Title only0.10
In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes.
TakeawayNot reported in abstract.
Animal2012Title only0.10
Defining biomaterial-driven design principles for bioabsorbable flow diverters: current state and perspectives.
FindingNot reported in abstract.
review2026Full text read0.70
JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy.
FindingNot reported in abstract.
Animal2026Full text read0.70
A brain-targeted biomimetic iron-porphyrin covalent organic framework nanoplatform for Alzheimer's disease: synergistic intervention via antioxidant, Aβ-regulating and immunomodulatory effects.
FindingCopper-ion chelation rate of 41.78%.
In vitro2026Full text read0.70
Systemic Copper Chelation Reduces Collagen Deposition and Preserves Secretory Function in Irradiated Mouse Salivary Glands.
FindingNot reported in abstract.
Animal2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching KLOW Protocol will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much KLOW Protocol is discussed should be drawn from it.